European generics group launches Code of Conduct
Following the adoption of the European Commission Guiding Principles Promoting Good Governance in the Pharmaceutical Sector initiated by the former Vice-President of the Commission, Antonio Tajani, the European Generic and Biosimilar medicines Association (EGA) is strengthening its commitment on ethics and transparency by introducing its Code of Conduct today.
The EGA General Assembly has formally adopted the EGA Code of Conduct, setting strong ethical standards to secure trustworthy and transparent relations between the industry and the health care community.
Adrian van den Hoven, the EGA’s director general, stated that “the generic and biosimilar medicines industries have fulfilled their commitment towards the EC Guiding Principles on Good Governance in the Pharmaceutical Sector by developing and implementing a leading industry ethical code covering interactions with the healthcare community.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Biosimilars
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze